慢性肾病及相关并发症治疗药物研究进展  

Progress on research and development of drug for chronic kidney disease and related comorbidities

作　　者：杨一歌 李鹤 张秀立 谭晓川 张宇佳[1] 郑稳生[1] YANG Yi-ge;LI He;ZHANG Xiu-li;TAN Xiao-chuan;ZHANG Yu-jia;ZHENG Wen-sheng(Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Tianjin University,Tianjin 100072,China)

机构地区：[1]北京协和医学院、中国医学科学院药物研究所,药物传输技术及新型制剂北京市重点实验室,北京100050 [2]天津大学,天津100072

出　　处：《药学学报》2022年第9期2682-2695,共14页Acta Pharmaceutica Sinica

基　　金：中国医学科学院医学与健康科技创新工程基金资助(2021-I2M-1-028).

摘　　要：慢性肾病(chronic kidney disease,CKD)是一种伴随着多种并发症(心血管疾病、代谢性酸中毒和贫血等)的进行性疾病,在人群中有着较高的发病率和死亡率。目前的主要治疗药物包括肾素-血管紧张素-醛固酮通路抑制剂及钠-葡萄糖共转运蛋白2抑制剂,都只能延缓CKD向终末期肾病的进展,而不能彻底治疗CKD。随着更多在CKD进展中起到关键作用的通路被发现,新的有前景的治疗方法也有望被研发出来。本文对CKD和其并发症的主要疗法及新兴疗法进行了总结,以期为CKD新疗法的研发提供支持。Chronic kidney disease(CKD)is a progressive disease with many complications(eg,cardiovascular disease and acidosis and anemia)and high morbidity and mortality occurs in the population.There is no cure for this disease,current treatments including renin-angiotensin-aldosterone pathway inhibitors and sodium-glucose co-transporter 2 inhibitors can only delay the progression to end-stage renal disease.With the identification of more key factors and mechanisms in CKD development,new potential therapeutic approaches for CKD can be developed.This review summarizes the mainstays of therapy and strategies for CKD and related comorbidities to support the development of novel treatments.

关 键 词：慢性肾病 并发症 药物研发 终末期肾病 临床试验药物 

分 类 号：R966[医药卫生—药理学]